相关实验视频
Updated: Jun 14, 2025

05:07
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
6.6K
洞察imidazo[1,2-a]pyridine衍生物作为抗癌剂的药用属性
Ankush Kumar1, Vishakha Sharma1, Tapan Behl1
1Amity School of Pharmaceutical Sciences, Amity University, Mohali, Punjab, India.
Archiv der Pharmazie
|September 2, 2024
概括
伊米达佐[1,2-a]皮里丁衍生物显示出作为新型抗癌剂的前景,准PI3K/mTOR和蛋白聚合等途径. 这些化合物提供了潜在的强效,有针对性的癌症治疗,降低了毒性.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 癌症仍然是全球领先的健康威胁,需要新的治疗方法,提高疗效和降低毒性.
- 现有的癌症疗法经常面临诸如耐药性和严重副作用等挑战.
- 伊米达佐[1,2-a]皮里丁 (IP) 支架是一种有前途的药,具有多种生物活性,包括抗癌潜力.
研究的目的:
- 审查和分析2016年至今期间开发的imidazo[1,2-a]pyridine衍生物的抗癌特征.
- 要突出这些IP化合物的结构-活性关系 (SARs).
- 强调IP部分在合理的癌症药物设计中的治疗潜力.
主要方法:
- 对已报告抗癌活性的合成IP衍生物的文献综述.
- 针对关键细胞通路的IP化合物的分析:酸-3-酶/哺乳动物拉巴胺的标 (PI3K/mTOR),蛋白酶B/哺乳动物拉巴胺的标 (Akt/mTOR),化脱酶 (ALDH) 和蛋白聚合.
- 评估结构-活性关系 (SARs),以了解结构修改对抗癌效能和选择性的影响.
主要成果:
- 许多IP衍生物通过各种机制表现出显著的抗癌活性.
- 在IP核心结构上,特定的替代模式对于调节强度和准特定路径至关重要.
- IP化合物显示出PI3K/mTOR,Akt/mTOR,ALDH和蛋白聚合的抑制剂的潜力,提供有针对性的治疗策略.
结论:
- 伊米达佐[1,2-a]氨酸衍生物是开发下一代抗癌药物的一类有价值的化合物.
- 对SAR的进一步探索可以导致基于IP的高强度和选择性抗癌剂的合理设计.
- 知识产权架构对未来的癌症疗法具有相当大的前景,具有潜在的最小毒性.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
238
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
238
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
Basicity of Heterocyclic Aromatic Amines
5.8K
Heterocyclic amines, where the N atom is a part of an alicyclic system, are similar in basicity to alkylamines. Interestingly, the heterocyclic amine having a nitrogen atom as part of an aromatic ring has much less basicity than its corresponding alicyclic counterpart. For this reason, as presented in Figure 1, piperidine (pKb = 2.8) is significantly more basic than pyridine (pKb = 8.8).
5.8K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181

